Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease

Surgical closure of the fistula was attempted twice without success. Because of worsening colitis, he was treated with 1 dose of infliximab (5 mg/kg/dose). Treatment options, including immunosuppressives, are based on established IBD therapies; however, caution needs to be taken in the CGD populatio...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2005-05, Vol.115 (5), p.1092-1094
Main Authors: Wang, Julie, Mayer, Lloyd, Cunningham-Rundles, Charlotte
Format: Article
Language:English
Subjects:
Abdomen
Adult
Anti-Bacterial Agents - therapeutic use
Antibiotics
Blood
Colitis - drug therapy
Colitis - etiology
Crohn's disease
Defects
Drug Therapy, Combination
Fungal infections
Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage
Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use
Granulomatous Disease, Chronic - complications
Hospitals
Humans
Inflammatory bowel disease
Injections, Subcutaneous
Male
Pain
Patients
Population
Rheumatic diseases
Success
Thoracic surgery
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Surgical closure of the fistula was attempted twice without success. Because of worsening colitis, he was treated with 1 dose of infliximab (5 mg/kg/dose). Treatment options, including immunosuppressives, are based on established IBD therapies; however, caution needs to be taken in the CGD population, because they are susceptible to infection as a result of their neutrophil dysfunction. Because fungal infections associated with TNF inhibitors have been reported, fungal prophylaxis is necessary for patients with CGD who are considered for this treatment.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2005.01.016